key: cord-0029202-4lo9s3ov
authors: Yeo, David; Murthy, Tal
title: Life Sciences Discovery and Technology Highlights
date: 2022-03-29
journal: SLAS Technol
DOI: 10.1177/2472630320937650
sha: 4092f35330f76c1fdfb2dda70c7d8ed37f270f49
doc_id: 29202
cord_uid: 4lo9s3ov

nan

generated negligible signal-demonstrating the specificity of the FET biosensor. The authors then propagated SARS-CoV-2 in culture, demonstrating an LOD of 16 PFU/mL with 4 logs of linear signal response.

Finally, the authors compared samples from infected and uninfected individuals in diluted samples containing as few as 242 copies/mL. Further optimization would be necessary to reduce signal noise. Thus, the FET biosensor is suitable for SARS-CoV-2 detection over a large dynamic range without sample processing. Such biosensing technologies show sufficient specificity and sensitivity and could be adapted to identify emerging infectious disease threats. (Seo, G.; et al. ACS Nano 2020, 14, 5135-5142.) 

Diagnosing COVID-19 is critical to restrict its spread. Detection of SARS-CoV-2 is most commonly and reliably performed by reverse transcription (RT) PCR, although it takes up to 2 days to complete. Chest x-rays (computed tomography [CT] ) are critical to identify symptoms in sick patients and can be carried out relatively quickly. Integrating clinical information in the diagnosis might further improve the diagnostic potential since CT is less effective during the early stages of the disease. In a smaller set of training tests (n = 279), a chest + artificial intelligence (AI) algorithm achieved an area under the curve (AUC) of 0.92 with a sensitivity of 84.3% compared with a specialist (senior thoracic radiologist) showing equally good performance. Among several methods, multilayer perceptron (MLP) classification

David Yeo 1 and Tal Murthy 2 was integrated into a neural network model to combine both radiological and clinical information. Combining CT results with clinical presentation can help to relieve the shortage of supplies and testing capacity, such as RT-PCR reagents, equipment, and even thoracic clinicians. Importantly, a prospective analysis in a Wuhan patient set identified bilateral lung opacities in 40 of 41 (98%) chest CTs. A recent study reported CT identifying lung abnormalities, while RT-PCR results remain negative.

A dataset of chest CT scans from 905 patients with COVID-19 concerns was obtained during January to March 2020 from 13 provinces all over China. Following the training of this model, the CT and clinical information model performed as well in terms of sensitivity compared with the senior thoracic radiologist, but it demonstrated significant improvement compared with the thoracic fellow. Of the 90 patients tested on the test set, 90 were classified similarly by the model and the senior thoracic radiologist. Of these 33 differences, 23 were forecasted as positive by the model but misclassified by the senior radiologist. Eleven patients were both jointly misclassified. Among the 145 negative patients, 113 were correctly classified by both. Thirty-two of the 145 were classified differently by both, with 7 classified as negative correctly by the model but diagnosed positive by the senior radiologist. Currently, the World Health Organization (WHO) rates nucleic acid tests like PCR as the most accurate method. However, it suffers from bottlenecks in testing capacity. Through use of the joint AI-clinical symptom model, patients can be triaged (prioritized) quickly in a shorter period compared with PCR tests.

While test results were promising, they could be improved by increasing the sample size and testing its generalizability on other patient populations. This method also fails to distinguish patients with COVID-19 from those with other causes of respiratory failure. Its accuracy will diminish in situations with lower COVID-19 prevalence. The increasing numbers of infected COVID-19 patients will provide more data for machine learning, which will increase its accuracy. Thus, such algorithmic methods may alleviate the strain placed on clinicians to identify those suffering from COVID-19 in an efficient manner as accurately as trained radiologists. (Mei, X.; et al. Nat. Med. 2020 . DOI: 10.1038/s41591-020-0931-3.)

Control measures to prevent COVID-19 infection depend on key epidemiology parameters such as serial interval (duration of symptom onset and transmission) and incubation period (time between infection and symptomatic onset). However, if the observed mean serial interval is shorter than the observed mean incubation period, a significant amount of transmission is likely to have occurred before subjects developed symptoms. This would render control measures such as isolation, contact tracing, and personal hygiene (including face masks) less effective.

While infectious diseases such as SARS-CoV are highly infectious around 7-10 days after symptom onset, others like influenza are infectious on or before onset. A set of data from 94 patients from a Guangzhou hospital were used. These were moderately ill, although none were considered "severe" or in "critical" condition. The serial interval was estimated to have a mean of 5.8 days and a mean incubation period of 5.2 days. This suggests that infectiousness started 2.3 days before symptom onset, peaking at 0.7 days before symptom onset. An estimated 44% of disease transmission occurred presymptom and declined by 7 days. Viral load also showed a similar decreasing pattern. Further simulations confirm that infectiousness 2 days before onset to 1 day after onset tallied the best with data. Comparison with data from Singapore and Tianjin similarly yields even higher proportions of presymptomatic transmission-48% and 62%, respectively.

Another study also suggests that 8 days after symptom onset, infectiousness declined, as seen from the lower infectiousness of derived viruses in cell culture infection assays. This study is potentially limited by patient recall-this is potentially subjective and overestimates the incubation period. The proportion of presymptomatic transmission would be artificially inflated in this case. Another source of uncertainty could emerge from the different treatment properties (antivirals, antibiotics, corticosteroids, immunomodulatory agents, and Chinese medicine preparations) that could modify virus shedding dynamics. This study strongly suggests greater inclusion criteria to capture potential transmission events 2-3 days before symptom onset for more effective control of the outbreak. (He, X.; et al. Nat. Med. 2020, 26, 672-675.) 

The novel coronavirus, SARS-CoV-2, caused the global pandemic of COVID-19. It is thought to have originated in bats, with the bat coronavirus RaTG13 showing 96% similarity and high similarity to two others. To date, very few cells have been able to cultivate coronaviruses, which makes their study difficult to perform. A readily accessible means to cultivate viruses in vitro will facilitate the study of bat coronaviruses that have high zoonotic potential. Adult human stem cellbased intestinal organoids have been shown to be expandable for 1 year and faithfully recapitulate the complexity of native human intestinal organoids. Given that COVID-19 symptoms include gastrointestinal symptoms like diarrhea, nausea, and vomiting, intestinal organoids were proposed as a means to establish in vitro cultures of SARS-CoV-2. The presence of bat coronaviruses found in bat fecal specimens suggest that bat intestine tissues were a target of infection. The authors have successfully grown bat intestine organoids (enteroids) previously, although they cannot be maintained in culture as long as human organoids.

The authors use clinical samples (nasopharyngeal, saliva) from COVID-19 patients to co-culture with bat and human organoids. With the progress of time, the viral load substantially increased up to 4 log units 64 h after inoculation (in bats). Moreover, inoculation into human organoids led to a similar 3-log increase of viral load with the presence of viral nucleocapsid prostein (NP)-positive cells. This suggests that bat and human enteroids are more suitable for virus cultivation compared with the commonly used Vero E6 cells. The cellular receptors that SARS-CoV-2 exploit for infection-angiotensin-converting enzyme 2 (ACE2) and TMPRSS2-were also significantly upregulated in differentiated/mature human and bat organoids. The bat organoids displayed increased viral load with time, which had a similarly increasing functional infectiousness on cultured cells. In-depth examination suggests that SARS-CoV-2 uses Villin-positive enterocyte cells to facilitate entry-as seen by the overlapping signal of virus NP. The inflammatory components IFNL2, IFNL3, CCR1, CCR8, IL16, IL3, and CXCL10 (IP10) were upregulated, whereas expression of the immune components CCR2, CCR5, and IL5 was suppressed. Importantly, this study demonstrates that bat and human enteric organoids can support the replication of SARS-CoV-2 and may facilitate the study of coronaviruses with high zoonotic potential. In addition, SARS-CoV-2 may infect gastrointestinal tissue as an additional route of infection. (Zhou, J.; et al. Nat Med. 2020 . DOI: 10.1038/ s41591-020-0912-6.)

COVID-19 disease management in Hong Kong SARS accounts for not only family members but also household pets. This gave the authors an opportunity to assess infection rates of the pets and determine the quarantine period and timing of release to their owners. The first dog was a 17-year-old Pomeranian with several preexisting lifethreatening conditions. With the dog's owner and domestic helper testing positive for COVID-19, the dog was transferred to a quarantine facility as well as the remaining members of the household. Nasal, oral, rectal, and fecal samples were collected and tested; meanwhile, the pet-dog remained bright and alert without any change in clinical condition. These samples exhibited a range of concentrations between 100 and 1000 RNA copies/mL, suggesting that they were less infectious, since this was <10 6 a typical infectious dose.

A second dog, a 2.5-year-old German Shepherd Dog (GSD) in good health, also tested positive for COVID-19.

Thereafter, both instances were tested for SARS-CoV-2 antibody by 90% plaque reduction neutralization tests (PRNT90). Sequenced nasal swab samples from the Pomeranian were genetically identical to samples obtained from the owner and domestic helper from the same household. Samples from the GSD were also found to be identical to the owner yet both sequences were distinct from each other. This suggests that viral transmission occurred within the same household. To further flesh out transmission events, the angiotensin-converting enzyme 2 (ACE2) receptor is shown to be similar between canines and humans. However, there is a dissimilarity in the amino acid sequence; however, these changes are not known to disrupt the interaction between SARS-CoV-2 and ACE2. While human-todog transmission is understood to have occurred, the GSD had another canine companion that was not infected, suggesting that transmission did not occur between the two dogs.

A wider survey with 4000 specimens also suggested that SARS-CoV-2 was not widely circulated among dogs, cats, and horses from households with infected members. Higher viral load and longer shedding were observed in nasal compared with oral samples, and cats had sufficiently large concentrations to potentially cause cat-to-cat viral transmission. A household pet cat was also identified to be positive for SARS-CoV-2. While the role that household pets play in overall disease transmission does not seem high, they could still serve as intermediate hosts to bridge transmission from bats (high reservoir of zoonotic diseases) to humans. Household pets could be tested to determine their role in virus transmissions in the future. 

SARS-CoV-2 is the infectious agent that has caused the COVID-19 global pandemic. Currently, no targeted therapeutics have been approved, but monoclonal antibodies that target vulnerable sites on viruses are becoming increasingly promising against infectious diseases. Most coronavirus-neutralizing antibodies target the spike (S) glycoprotein decorating the virus that facilitates entry into host cells. Neutralizing antibodies can act strongly by targeting the receptor interaction site S1, disabling receptor interactions. S proteins of SARS-CoV and SARS-CoV-2 (77.5% similarity) bind the human angiotensin-converting enzyme 2 (ACE2) as a host receptor, triggering conformational changes to enable membrane fusion.

From antibody-containing supernatants of 51 SARS-S hybridomas from immunized transgenic H2L2 mice, four supernatants cross-reacted with the SARS2-S1, from which one candidate, 47D11, cross-neutralized infection of pseudotyped VSVs (vesicular stomatitis viruses). The chimeric 47D11 candidate was then reformatted to a recombinant human one. Addition of humanized 47D11 potently inhibited SARS-S and SARS2-S pseudotyped VSVs with a halfmaximal inhibitory concentration (IC 50 ) of 0.061 µg/mL. The IC 50 values of authentic viruses were 0.19 and 0.57 µg/mL for SARS-CoV and SARS-CoV-2, respectively. It was shown to target the S1B receptor-binding domain. Further investigations suggest that 47D11 neutralizes both SARS-CoV and SARS-CoV-2 through unknown mechanisms different from receptor-binding interference (RBI). These mechanisms may be a result of S inactivation through antibody-induced destabilization.

Since 47D11 has cross-reactivity with the two viruses, the antibody is more likely to target the conserved core structure of the S1B RBD. This results in antibody binding farther away from the RBI, opening up possibilities for combination treatments with noncompeting, potent neutralizing antibodies that target receptor-binding domains at lower dosages. This is the first report of a (human) monoclonal antibody that neutralizes SARS-CoV-2 that has cross-reactivity with SARS-CoV. This is due to it targeting the conserved epitope on the S RBD. This antibody will be useful in the development of antigen detection and serology assays. 47D11 may be developed to deal with new and emerging threats from related coronaviruses. (Wang, C.; et al. Nat. Commun. 2020 , 11, 2251 

Following the emergence of COVID-19, therapeutic agents have been sought after, but none have been shown to be efficacious. The drug remdesivir, an inhibitor against RNA polymerase, has been shown to have inhibitory activity against pathogenic coronaviruses such as SARS-CoV and its middle eastern counterpart, MERS-CoV. Promisingly, it was shown to inhibit SARS-CoV-2 in vitro. A phase 3, randomized, double-blind, placebo-controlled trial was performed. A total of 1107 patients were assessed for eligibility; 1063 were randomized and assigned to remdesivir and a placebo group. Of these, 391 from the remdesivir group and 340 from the placebo group completed the trial (lasting 29 days), recovered, or died.

The mean age of patients was 58.9 years with 64.3% male and ~80% from North America, 15% from Europe, and 5% from Asia. Most patients had either 1 (27%) or 2 or more (52%) preexisting conditions, such as hypertension, obesity, and type 2 diabetes. Taking remdesivir led to a shorter recovery time (median, 11 days) compared with the placebo group (15 days) for the primary outcome. A secondary outcome, mortality, was improved (7.1% in 14 days) by remdesivir compared with the placebo group (11.9%). Whereas the treatment group had serious respiratory failure adverse events in 5.2% of patients, the placebo group had such events in 8% of the cohort. Hypotension, viral pneumonia, and acute kidney injury were other commonly observed adverse events. Generally, remdesivir did not significantly reduce the occurrence of adverse events compared with the placebo.

Given the strength of remdesivir, the results were made public promptly for health and safety reasons. Analysis of the data showed that identifying COVID-19 cases earlier allowed antiviral treatment to start before the pulmonary disease progressed to a stage where mechanical ventilation was required. In a clinical trial conducted in China, remdesivir treatment was not significantly different compared with placebos; however, the trial failed to complete full enrollment (due to the outbreak ending), with smaller numbers of subjects and thus a lower power. It is worth noting that the trial was conducted under a difficult time with regard to restricted travel, with hospitals restricting the access of researchers, with training and monitoring visits performed remotely. Certain sites were also inadequately supplied with personal protective equipment and other supplies, consumables like swabs, and so on.

The Food and Drug Administration (FDA) has made remdesivir available under an emergency-use authorization for treating adults and children suffering from COVID-19. Importantly, the high rates of mortality from remdesivir suggest that a potential treatment could combine it with other therapeutic approaches and/or combinations of other antiviral agents to improve COVID-19 patient outcomes. 

The COVID-19 pandemic is widespread and has severely affected almost every country, calling for the urgent development of a preventative vaccine. To address this issue, synthetic DNA development can be accelerated by designing multiple candidates for preclinical testing, scalable manufacturing of large quantities of product, and regulatory benefits. Synthetic DNA has further benefits including being temperature stable and cold-chain free. The authors leverage prior experience working on the SARS-CoV and in developing a MERS-CoV vaccine. These DNA approaches have driven neutralizing antibody (nAb) responses in small and large animal models.

The SARS-CoV-2 spike (S) structure is highly similar to that of SARS-CoV and shares similarity with the MERS-CoV S. These nAbs targeted at the receptor-binding domain (RBD) appear to have great neutralizing potency. This suggests that the RBD is an important target for vaccine development. Plasmids were generated to encode four sequences for S proteins. These were utilized on COS-7 and HEK-293T cells and found to generate the predicted S protein (140-142 kDa). These verify S RNA and protein expression using the candidate vaccine constructs. One of these constructs, pGX9501, was selected for immunological studies for the broader coverage it could potentially provide. These were evaluated in BALB/c mice, by delivery with the CELLECTRA device. From blood sera, IgG binding was observed against the SARS-CoV-2 S proteins with limited binding to those from SARS-CoV. These were observed at day 14 of immunization from a single INO-4800 dose. A neutralization assay based on luciferase expressing pseudoviruses also showed an ID 50 average titer of 92.2 and reduced neutralizing activity in serial dilutions.

The immunogenicity of INO-4800 was tested on an intradermal guinea pig vaccine model. The subjects were treated on days 0, 14, and 28 with 100 µg of INO-4800 and collected on day 35 or 42 to evaluate sera-neutralizing activity. Both pseudoviruses and wild-type SARS-CoV-2 expressed a strong response. The INO-4800-induced antibodies were assayed using an angiotensin-converting enzyme 2 (ACE2) inhibition enzyme-linked immunosorbent assay (ELISA) test as a surrogate for neutralization. ACE2 was found to bind the SARS-CoV-2 S protein with a half-maximal drug response of 0.025 µg/mL. In immunized mice, INO-4800 antibodies competed with ACE2 binding to SARS-CoV-2 S proteins. Similarly, the antibodies from INO-4800-immunized guinea pigs also blocked ACE2 binding in a dilution-dependent manner. This direct demonstration of the INO-4800 antibodies blocking ACE2 interaction was key because it is widely known to facilitate host infection.

In both immunized mice and guinea pigs, bronchoalveolar lavage (BAL) fluid was collected and SARS-CoV-2 anti-S proteins were detected, suggesting that INO-4800 generated protective antibodies against lower respiratory disease since it was found in the lung mucosa. Furthermore, specific T-cell responses were identified against SARS-CoV-2, while no cross-reactive T-cell responses were found against MERS-CoV and weaker reactions were found against SARS-CoV. Preclinical development to the INO-4800 vaccine demonstrated robust immune responses in mice and guinea pigs. This demonstrates a highly effective and responsive method to develop candidates to deal with emergent viruses.

The nature of synthetic DNA candidates is a plug-andplay process that facilitates rapid vaccine development. Because it is created via synthetic DNA, development can begin within days of receiving the genomic sequence. It also circumvents difficulties in vaccine production capacity, such as eggs and cell culture. As a DNA product, it can be stored for >4 years at 2-8 °C, for 1 year at room temperature, and for 1 month at body temperature. This significantly relieves the need for cold-chain storage and delivery. This suggests that INO-4800 is a worthy candidate for COVD-19 clinical trials. (Smith, T. R. F.; et al. Nat. Commun. 2020 , 11, 2601 

As COVID-19 worsens into a global pandemic, several therapeutic agents are under investigation for their antiviral efficacy. Convalescent plasma has been used as a treatment against the Ebola virus and Middle East respiratory syndrome (MERS) coronavirus. Other viral infections such as SARS-CoV, H5N1 avian influenza, and H1N1 influenza have benefitted from the usage of convalescent plasma. In particular, influenza A (H1N1) patients treated with convalescent plasma had reduced respiratory tract viral load, serum cytokine response, and mortality. SARS patients had a higher rate of hospital discharge when administered with it.

Patients who recovered from SARS-CoV-2 were invited to donate convalescent plasma. These donors were diagnosed with COVID-19 through laboratory tests (e.g., RT-PCR) and subsequently tested negative for SARS-CoV-2 and respiratory viruses such as hepatitis B, hepatitis C, HIV, and syphilis. Five patients were administered convalescent plasma between 10 and 22 days following admission, after treatment with antiviral agents and steroids. Within 1 day of transfusion, the Ct value (quantity of SARS-CoV-2) increased, signifying a decrease in its concentration within the sample.

The SOFA (Sequential Organ Failure Assessmentrespiratory, coagulation, hepatic, cardiovascular, central nervous system, and kidney) score similarly decreased, suggesting they were in less critical condition. The patients were also found to have a higher arterial oxygen concentration. Body temperature also declined to a normal range on the third day after transfusion. Inflammatory biomarkers including C-reactive protein (CRP), procalcitonin, and IL-6 of four of five patients also decreased. Severe pneumonia and pulmonary lesions were also gradually resolved. IgG and IgM in the patient's sera also showed higher antibody titers. Administration of convalescent plasma also allowed patients to be taken off mechanical ventilation and hastened their discharge.

High viral loads often coincide with disease severity and progression. Virus-specific neutralizing antibodies accelerate virus clearance, preventing entry into target cells, thereby restricting and clearing viruses from the host. As determined by enzyme-linked immunosorbent assays (ELISAs), all donated plasma had high virus-specific IgG and IgM titers that significantly increased after plasma transfusion. This suggested that convalescent plasma contributed to virus clearance and improved symptoms. Despite the promising results, there are some limitations, including the limited number of patients, the lack of controls, the lack of clarity whether

and the uncertainty of the timing of administration and whether convalescent plasma can reduce fatality rates. Regardless, the seemingly beneficial effects of convalescent plasma suggest that it deserves further evaluation in clinical trials

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors received no financial support for the research, authorship, and/or publication of this article.